As reported by Health News Digest, researchers at The Ohio State University Comprehensive Cancer Center have developed a medicated oral patch that allows a chemoprevention drug to be released directly into precancerous lesions in the mouth over an extended time.
In the study published online by the journal Pharmaceutical Research, Dr. Susan Mallery and co-investigator, Dr. Peter Larsen of Ohio State, tested a patch using simulated saliva as well as lab animals.
From the Heath News Digest article -
The study evaluated the drug fenretinide, a synthetic derivative of vitamin A that has highly promising anti-cancer properties. Until now, scientists have failed to achieve a therapeutic, systemic dose of fenretinide because of drug toxicity and rapid release from the body. By using a new mucoadhesive patch invented by a team from Ohio State’s Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and the University of Michigan, the researchers developed a delivery system that can provide continuous drug therapy to saliva-coated oral tissue.
In an online report published March 7 in the Journal of Clinical Oncology, the authors found an alarming trend: incidences of oral tongue cancer climbed 111% in young white females. This patch is an important step in fighting this rising cancer epidemic.
For more on this story see: Medicated Patch Shows Promise in Oral Cancer Prevention


New research from the Harvard School of Public Health has linked obesity with gum disease.

Setting Dental Fees for Maximum Case Acceptance
$10,000 a Month Chart Audit
DIY Office Brochure
Maximize Case Acceptance
Net $100,000 a Year From Your Telephone Book Ad
Maximize Your Marketing: Target High-Value Patients
Turn Your Front Desk into a Marketing Machine
Structuring a Dental Associate Program
Designing the $1,000,000 Dental Practice Sign
Internal Marketing & Communications